Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Mizuho analyst Graig Suvannavejh maintains Terns Pharma (NASDAQ:TERN) with a Outperform and raises the price target from $32...
Barclays analyst Etzer Darout maintains Terns Pharma (NASDAQ:TERN) with a Overweight and raises the price target from $27 to...
Terns Pharma (NASDAQ:TERN) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.30) ...
Truist Securities analyst Srikripa Devarakonda reiterates Terns Pharma (NASDAQ:TERN) with a Buy and raises the price target ...
BMO Capital analyst Etzer Darout maintains Terns Pharma (NASDAQ:TERN) with a Outperform and raises the price target from $15...
Barclays analyst Etzer Darout maintains Terns Pharma (NASDAQ:TERN) with a Overweight and raises the price target from $14 to...
HC Wainwright & Co. analyst Andres Y. Maldonado upgrades Terns Pharma (NASDAQ:TERN) from Neutral to Buy and announces $2...
